Organogenesis Holdings Inc. (FRA:2PQ)
| Market Cap | 459.34M |
| Revenue (ttm) | 396.51M |
| Net Income (ttm) | -7.86M |
| Shares Out | n/a |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | 16.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 82 |
| Open | 4.360 |
| Previous Close | 4.360 |
| Day's Range | 3.920 - 4.360 |
| 52-Week Range | 2.300 - 6.000 |
| Beta | n/a |
| RSI | 32.97 |
| Earnings Date | Feb 27, 2026 |
About Organogenesis Holdings
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic fo... [Read more]
News
Organogenesis, MiMedx among decliners as Medicare to pull skin substitute LCDs
Organogenesis Initiates BLA Submission For ReNu In Knee Arthritis
(RTTNews) - Organogenesis Holdings Inc. (ORGO) ,a regenerative medicine company announced that it has initiated the submission of a Biologics License Application or BLA to the US Food and Drug Adminis...
Organogenesis (ORGO) Advances ReNu BLA Submission for Knee Arthritis
Organogenesis (ORGO) Advances ReNu BLA Submission for Knee Arthritis
Organogenesis starts rolling submission for ReNu allograft for knee arthritis
Organogenesis (ORGO) Begins Rolling Submission for FDA Approval of ReNu
Organogenesis (ORGO) Begins Rolling Submission for FDA Approval of ReNu
Organogenesis Announces Initiation of Biologics License Application for ReNu
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a l...
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 Initial modules submitted to FDA under rolling review; final modules expected in the first half ...
Organogenesis To File Rolling BLA For ReNu Following FDA Meeting
(RTTNews) - Organogenesis Holdings Inc. (ORGO) announced the successful completion of a planned Type-B meeting with the U.S. FDA, confirming that the company may initiate a rolling Biologics License A...
Organogenesis (ORGO) Advances ReNu Program With FDA Filing
Organogenesis (ORGO) Advances ReNu Program With FDA Filing
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading r...
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading ...
Organogenesis: High-Tech Skin Substitute Company On Sale
Organogenesis (ORGO) Q3 Earnings Exceed Expectations with Strong Product Sales
Organogenesis (ORGO) Q3 Earnings Exceed Expectations with Strong Product Sales
Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
Organogenesis Stock Surges 54% After Q3 Revenue Beat And Guidance Raise
(RTTNews) - Organogenesis Holdings Inc. (ORGO) jumped 53.72% to $5.98, up $2.09, after reporting strong third-quarter 2025 results and revising its full-year outlook.
Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Positioning Amid Challenges
Q3 2025 Organogenesis Holdings Inc Earnings Call Transcript
Q3 2025 Organogenesis Holdings Inc Earnings Call Transcript
Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings: EPS of $0. ...
Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings: EPS of $0.11 Beats Estimate, Revenue Surges to $150.5 Million
Organogenesis Holdings GAAP EPS of $0.11 beats by $0.05, revenue of $150.5M beats by $16.4M
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...
Organogenesis Applauds CMS's Significant Step In Payment Reform
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond With evidence-based portfolio including ...
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commer...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors a...
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
LOS ANGELES--(BUSINESS WIRE)--Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO.